Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components

Specific Anti-SARS-CoV-2 Humoral and Cellular Immune Responses After Booster Dose of BNT162b2 Pfizer-BioNTech mRNA-Based Vaccine: Integrated Study of Adaptive Immune System Components

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), is modifying human activity all over the world with significant health and economic burden. The advent of the SARS-CoV-2 pandemic prompted the scientific community to learn the virus dynam...

Full description

Bibliographic Details
Main Authors: Rosalia Busà, Maria Concetta Sorrentino, Giovanna Russelli, Giandomenico Amico, Vitale Miceli, Monica Miele, Mariangela Di Bella, Francesca Timoneri, Alessia Gallo, Giovanni Zito, Daniele Di Carlo, Pier Giulio Conaldi, Matteo Bulati
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
mRNA vaccine
BNT162b2
booster dose
B cells
T cells
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.856657/full

Similar Items

Similar Items